Articles citing this paper
Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia
David G. Regan A D , David J. Philp B , Jane S. Hocking C and Matthew G. Law A
+ Author Affiliations
- Author Affiliations
A National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2052, Australia.
B The National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT 0200, Australia.
C Key Centre for Women’s Health in Society, School of Population Health, University of Melbourne, Melbourne, Vic. 3010, Australia.
D Corresponding author. Email: d.regan@unsw.edu.au
Sexual Health 4(3) 147-163 https://doi.org/10.1071/SH07042
Submitted: 19 June 2007 Accepted: 22 June 2007 Published: 23 August 2007
42 articles found in Crossref database.
Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer
Rahma Osama E,
Herrin Vincent E,
Ibrahim Rami A,
Toubaji Anton,
Bernstein Sarah,
Dakheel Omar,
Steinberg Seth M,
Eid Rasha Abu,
Mkrtichyan Mikayel,
Berzofsky Jay A, Khleif Samir N
Journal of Translational Medicine. 2014 12(1).
Evaluating Human Papillomavirus Vaccination Programs
Donovan Basil, Guy Rebecca J.
Sexually Transmitted Diseases. 2013 40(4). p.290
Surveillance of Vaccination Coverage among Adult Populations — United States, 2015
Williams Walter W.,
Lu Peng-Jun,
O’Halloran Alissa,
Kim David K.,
Grohskopf Lisa A.,
Pilishvili Tamara,
Skoff Tami H.,
Nelson Noele P.,
Harpaz Rafael,
Markowitz Lauri E.,
Rodriguez-Lainz Alfonso, Fiebelkorn Amy Parker
MMWR. Surveillance Summaries. 2017 66(11). p.1
A revision of sexual mixing matrices in models of sexually transmitted infection
Walker Robert,
Nickson Carolyn,
Lew Jie‐Bin,
Smith Megan, Canfell Karen
Statistics in Medicine. 2012 31(27). p.3419
Projecting the Need for Gynecologic Oncologists for the Next 40 Years
Wallace Amy H.,
Havrilesky Laura J.,
Valea Fidel A.,
Barnett Jason C.,
Berchuck Andrew, Myers Evan R.
Obstetrics & Gynecology. 2010 116(6). p.1366
Sexual risk assessment is not helpful for recommendations on human papillomavirus vaccination
Skinner Rachel, Brotherton Julia
Therapy. 2008 5(3). p.283
Prevention strategies against human papillomavirus in males
Garland Suzanne M.
Gynecologic Oncology. 2010 117(2). p.S20
Potential Benefits of Second-Generation Human Papillomavirus Vaccines
Kiatpongsan Sorapop,
Campos Nicole Gastineau,
Kim Jane J., Scheurer Michael
PLoS ONE. 2012 7(11). p.e48426
Herd immunity: recent uses in vaccine assessment
Gonçalves Guilherme
Expert Review of Vaccines. 2008 7(10). p.1493
The ethics of implementing human papillomavirus vaccination in developed countries
Malmqvist Erik,
Helgesson Gert,
Lehtinen Johannes,
Natunen Kari, Lehtinen Matti
Medicine, Health Care and Philosophy. 2011 14(1). p.19
Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries
Natunen Kari,
Lehtinen Johannes,
Namujju Proscovia,
Sellors John, Lehtinen Matti
Infectious Diseases in Obstetrics and Gynecology. 2011 2011 p.1
Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study
Chow Eric P F,
Machalek Dorothy A,
Tabrizi Sepehr N,
Danielewski Jennifer A,
Fehler Glenda,
Bradshaw Catriona S,
Garland Suzanne M,
Chen Marcus Y, Fairley Christopher K
The Lancet Infectious Diseases. 2017 17(1). p.68
Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection
Korostil Igor A.,
Peters Gareth W.,
Law Matthew G., Regan David G.
Vaccine. 2013 31(15). p.1931
A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
Kulasingam Shalini,
Connelly Luke,
Conway Elizabeth,
Hocking Jane S.,
Myers Evan,
Regan David G.,
Roder David,
Ross Jayne, Wain Gerard
Sexual Health. 2007 4(3). p.165
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands
Rogoza R.M.,
Westra T.A.,
Ferko N.,
Tamminga J.J.,
Drummond M.F.,
Daemen T.,
Wilschut J.C., Postma M.J.
Vaccine. 2009 27(35). p.4776
Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study
Chow Eric P F,
Danielewski Jennifer A,
Fehler Glenda,
Tabrizi Sepehr N,
Law Matthew G,
Bradshaw Catriona S,
Garland Suzanne M,
Chen Marcus Y, Fairley Christopher K
The Lancet Infectious Diseases. 2015 15(11). p.1314
Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective
Zhang Lei,
Regan David G.,
Ong Jason J.,
Gambhir Manoj,
Chow Eric P.F.,
Zou Huachun,
Law Matthew,
Hocking Jane, Fairley Christopher K.
Vaccine. 2017 35(37). p.4923
The predicted impact of vaccination on human papillomavirus infections in Australia
Smith Megan A.,
Canfell Karen,
Brotherton Julia M.L.,
Lew Jie‐Bin, Barnabas Ruanne V.
International Journal of Cancer. 2008 123(8). p.1854
Mothers’ and their daughters’ use of preventive measures against cervical cancer
Sander Bente Braad,
Vázquez-Prada Miguel,
Rebolj Matejka,
Valentiner-Branth Palle, Lynge Elsebeth
Scandinavian Journal of Public Health. 2015 43(4). p.415
Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies
Ben Hadj Yahia Mohamed-Béchir,
Jouin-Bortolotti Anaïs, Dervaux Benoît
Clinical Drug Investigation. 2015 35(8). p.471
HPV and Cervical Cancer (2012)
Update on Human Papillomavirus (HPV) Vaccines
Dawar Dr. M.,
Harris Ms. T., McNeil Dr. S.
Canada Communicable Disease Report. 2012 38(ACS-1). p.1
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
Donovan Basil,
Franklin Neil,
Guy Rebecca,
Grulich Andrew E,
Regan David G,
Ali Hammad,
Wand Handan, Fairley Christopher K
The Lancet Infectious Diseases. 2011 11(1). p.39
National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program
Brotherton Julia M. L.,
Leask Julie,
Jackson Cath,
McCaffery Kirsten, Trevena Lyndal J.
Sexual Health. 2010 7(3). p.291
HPV Vaccine and College-Age Men: A Scoping Review
Laserson Alyssa K.,
Oliffe John L.,
Krist Jennifer, Kelly Mary T.
American Journal of Men's Health. 2020 14(6). p.155798832097382
Models of cervical screening in the era of human papillomavirus vaccination
Canfell Karen
Sexual Health. 2010 7(3). p.359
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis
Van de Velde Nicolas,
Brisson Marc, Boily Marie-Claude
Vaccine. 2010 28(33). p.5473
Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model
Baussano Iacopo,
Dillner Joakim,
Lazzarato Fulvio,
Ronco Guglielmo, Franceschi Silvia
Infectious Agents and Cancer. 2014 9(1).
Epidemiological and Economic Impact of Human Papillomavirus Vaccines
Jeurissen Sarah, Makar Amin
International Journal of Gynecological Cancer. 2009 19(4). p.761
Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?
Skinner S Rachel,
Garland Suzanne M,
Stanley Margaret A,
Pitts Marian, Quinn Michael A
Medical Journal of Australia. 2008 188(4). p.238
Modeling Cervical Cancer Prevention in Developed Countries
Kim Jane J.,
Brisson Marc,
Edmunds W. John, Goldie Sue J.
Vaccine. 2008 26 p.K76
What can surveillance of genital warts tell us?
Fairley Christopher K., Donovan Basil
Sexual Health. 2010 7(3). p.325
Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus
Korostil Igor A.,
Peters Gareth W.,
Cornebise Julien, Regan David G.
Statistics in Medicine. 2013 32(11). p.1917
Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
Dasbach Erik J,
Largeron Nathalie, Elbasha Elamin H
Expert Review of Pharmacoeconomics & Outcomes Research. 2008 8(5). p.491
‘Is it like one of those infectious kind of things?’ The importance of educating young people about HPV and HPV vaccination at school
Davies Cristyn,
Skinner Susan Rachel,
Stoney Tanya,
Marshall Helen Siobhan,
Collins Joanne,
Jones Jane,
Hutton Heidi,
Parrella Adriana,
Cooper Spring,
McGeechan Kevin, Zimet Gregory
Sex Education. 2017 17(3). p.256
Epidemiological impact of the human papillomavirus vaccination program on genital warts in Portugal: A retrospective, chart review study
Fernandes Cândida,
Alves João,
Rodrigues Ana, Azevedo Jacinta
Vaccine. 2022 40(2). p.275
Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective
Regan David G.,
Philp David J., Waters Edward K.
Sexual Health. 2010 7(3). p.368
Clinical trials of human papillomavirus vaccines and beyond
Lehtinen Matti, Dillner Joakim
Nature Reviews Clinical Oncology. 2013 10(7). p.400
Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine
Marra Fawziah,
Cloutier Karine,
Oteng Bridgette,
Marra Carlo, Ogilvie Gina
PharmacoEconomics. 2009 27(2). p.127
The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models
Korostil Igor A,
Garland Suzanne M,
Law Matthew G, Regan David G
BMC Infectious Diseases. 2013 13(1).
Testing previous model predictions against new data on human papillomavirus vaccination program outcomes
Smith Megan A, Canfell Karen
BMC Research Notes. 2014 7(1).
Should Cervical Cancer Screening be Performed Before the Age of 25 Years?
Moscicki Anna-Barbara,
Perkins Rebecca B.,
Saville Marion, Brotherton Julia M. L.
Journal of Lower Genital Tract Disease. 2018 22(4). p.348
